FDA Grants Priority Review to Pfizer's Prostate Cancer Combo
PFE is trading near its 52-week low of $23.11 (7.7% above the low).
Summary
The FDA accepted Pfizer's application for expanded use of its prostate cancer combination therapy and granted priority review, shaving months off the standard timeline. This follows strong Phase 3 data for Talzenna and Xtandi reported in May, which showed over 50% improvement in radiographic progression-free survival. Priority review signals the agency sees a significant unmet need, and an approval could open a larger patient population. The decision date is likely in late 2026, adding a near-term catalyst to Pfizer's oncology pipeline.
At the time of this announcement, PFE was trading at $24.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $141.5B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.